No Data
No Data
Cynata Therapeutics Concludes Patient Enrolment in Diabetic Foot Ulcer Wound Dressing Product Trial
Cynata Therapeutics (ASX:CYP) completed patient enrolment in its Phase 1 clinical trial of its topical wound dressing product candidate, CYP-006TK, in diabetic foot ulcers, according to a Monday filin
Cynata Therapeutics Receives EU Approval for CYP-001 Phase 2 Trial
Cynata Therapeutics (ASX:CYP) has secured regulatory and ethics approval from the European Union for the phase 2 clinical study of CYP-001 in high-risk acute graft versus host disease, according to a
Cynata Therapeutics' Breakthrough in Regenerative Medicine
Peter Milios: I am Peter Milios from the Finance News Network, and today I am talking with Cynata Therapeutics. Cynata is a clinical stage stem cell and regenerative medicine company. Their ASX code i
Cynata Therapeutics Doses First Patient in Phase Two Trial of Cellular Therapy; Shares Rise 5%
Cynata Therapeutics (ASX:CYP) dosed the first patient in its phase two trial investigating the use of the cellular therapy CYP-001 in patients with graft versus host disease. The randomized trial aims
Cynata Therapeutics Names Chief Business Officer; Shares Plunge 14%
Cynata Therapeutics (ASX:CYP) appointed Mathias Kroll as chief business officer, effective mid-April, the clinical-stage biotechnology company said Thursday. Kroll will join Cynata from QIMR Berghofer
Companies Like Cynata Therapeutics (ASX:CYP) Could Be Quite Risky
No Data